Popular Sleep Aid’s Quiet Dependence Warning

Vitamin and supplement bottles on store shelves — Photo: Sheila Fitzgerald / Shutterstock

Mice given a popular sleep cannabinoid twice a day developed tolerance and showed withdrawal symptoms within less than a week.

Quick Take

A new animal study found mice built tolerance to cannabinol (CBN) and showed withdrawal-like symptoms after researchers blocked their cannabinoid receptors.
CBN is the active ingredient marketed in many popular cannabis sleep gummies sold over the counter.
Researchers and the university behind the study say the results come from mice, not people, so human risk remains unproven.
Separate human trials of oral CBN found no serious side effects, but those studies only lasted days or weeks.

What The Mouse Study Actually Found

Researchers at the University of Connecticut and RTI International gave adult mice CBN twice a day for five days, then ran behavior tests. The mice grew tolerant to CBN’s effects on movement, pain response, and body temperature. On day six, scientists gave the mice a drug called rimonabant, which blocks cannabinoid receptors. The mice then showed head twitches, paw tremors, and more struggling during stress tests — all signs linked to withdrawal.

The study also found something scientists call cross-tolerance. Mice treated with CBN responded less to a different cannabinoid drug entirely, and CBN produced effects nearly identical to THC in certain brain-response tests. That suggests CBN works through some of the same pathways as THC, the compound that gets users high, even though CBN itself is not considered intoxicating at typical gummy doses.

Why This Matters For Millions Of Gummy Users

CBN has become a go-to ingredient in sleep aids sold at pharmacies, grocery stores, and online retailers nationwide. It is marketed as a gentle, non-intoxicating alternative to melatonin or prescription sleep drugs. If repeated use quietly builds tolerance or dependence in people the way it did in mice, millions of nightly users could be at risk without ever reading a warning label.

University of Connecticut researcher Lesley-Ann Kinsey, who worked on the study, said more research is needed to know how CBN affects people, especially at high doses or over long stretches of time. That is a fair and honest caveat. It is also exactly the kind of caution the supplement industry rarely volunteers on its own packaging.

The Limits Scientists Are Being Upfront About

The mouse experiments do not prove that CBN causes dependence or withdrawal in humans. The mice were also given CBN by injection at relatively high doses, not swallowed in gummy form the way consumers take it. Withdrawal symptoms only appeared after researchers chemically forced the issue with rimonabant, not after the mice simply stopped taking CBN on their own, which is how real people would actually quit.

Human studies paint a calmer picture so far. A randomized, placebo-controlled trial testing CBN for insomnia reported no serious side effects, though researchers admitted the trial ran too short to judge long-term safety. Another placebo-controlled study of oral CBN found no meaningful difference in anxiety, pain, or side-effect rates compared to a placebo pill. A broader review found no completed human trials have tracked psychiatric outcomes from CBN use at all, leaving a real gap in the record.

Popular Sleep Supplement Cannabinol Could Come With an Unexpected Catch – Dependence, Scientists Warn | University of Connecticut, SciTechDaily

A cannabis compound sold to help people sleep caused withdrawal symptoms in mice after just three days of repeated use.

Researchers at… pic.twitter.com/cl4l4jalPg

— Owen Gregorian (@OwenGregorian) October 25, 2026

Common sense suggests a middle path here. Nobody needs to panic and toss out a bottle of sleep gummies tonight. But consumers deserve honest labeling, and companies profiting from CBN sales have every financial incentive to downplay a tolerance warning that could hurt demand. Until researchers run proper human trials on real-world doses over real-world timeframes, buyer caution, not blind trust in a gummy wrapper, is the responsible call.